Results 81 to 90 of about 5,633 (190)
Repurposing Purine Analog Antivirals to Modulate Serum Uric Acid: Evidence From Real‐World Data
Clinical and Translational Science, Volume 19, Issue 6, June 2026.ABSTRACT Xanthine oxidase (XO) inhibitors remain the standard pharmacologic therapy for hyperuricemia. However, additional enzymatic components of the purine degradation pathway may contribute to uric acid synthesis. Guanine deaminase (GD) catalyzes the conversion of guanine to xanthine, providing substrate for downstream oxidation by XO.
Joseph Magagnoli +5 more
wiley +1 more source
, 2014 Tadashi Sofue,1 Masashi Inui,2 Taiga Hara,1 Yoko Nishijima,1 Kumiko Moriwaki,1 Yushi Hayashida,3 Nobufumi Ueda,3 Akira Nishiyama,4 Yoshiyuki Kakehi,3 Masakazu Kohno1 1Division of Nephrology and Dialysis, Department of Cardiorenal and Cerebrovascular ...
Inui M +9 more
core
Study on Ameliorative Effect of Febuxostat on Gout Induced Model in Broiler Chicks
, 2017 This work was conducted on six groups of day-old Cobb-400 broiler chicks to study the ameliorative effect of febuxostat on gout induced model. Clinical signs were noticed in birds of diclofenac control group II and low dose febuxostat treated group IV ...
D. J. Dave +4 more
core +1 more source
The Urate-lowering Efficacy and Safety of Febuxostat in Korean Patients with Gout [PDF]
, 2013 Objective: To compare the urate-lowering efficacy and the safety of febuxostat, allopurinol and placebo in Korean patients with gout for 4 weeks. Methods: Subjects (n=182) with gout were randomized to febuxostat (40, 80, 120 mg), allopurinol 300 mg ...
이수곤
core +1 more source
Arthritis Research & Therapy, 2019 Background This study investigates the association between exposure to urate-lowering drugs (ULDs) and progression and recovery from chronic kidney disease (CKD). Methods We identified 5860 incident gout patients at Chang Gung Memorial Hospital from 2012
Ting-Ting Chung +9 more
doaj +1 more source
Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
, 2010 Lada Beara-Lasic1,3, Michael H Pillinger2,3, David S Goldfarb1,31Divisions of Nephrology and 2Rheumatology, Department of Medicine, NYU Langone Medical Center, New York, NY, USA; 3Department of Medicine, New York Harbor VA Health Care System, New York ...
David S Goldfarb +2 more
core
Febuxostat improves outcome in a rat model of cancer cachexia
, 2015 Background Activity of xanthine oxidase is induced in cancer cachexia, and its inhibition by allopurinol or oxypurinol improves survival and reduces wasting in the Yoshida hepatoma cancer cachexia model.
Springer, Jochen +8 more
core +1 more source
A pharmacokinetic‐pharmacodynamic study of a single dose of febuxostat in healthy subjects
, 2020 Aims To examine the pharmacokinetic‐phamacodynamic (PK‐PD) relationships of plasma febuxostat and serum urate and the effect of a single dose of the drug on renal excretion and fractional clearance of urate (FCU).
Sophie L. Stocker +15 more
core +1 more source
, 2018 We readwith interest the review by Robinson et al. [1] on the role of febuxostat in the treatment of hyperuricemia. The authors discuss data from phase II and III clinical trials on the efficacy and safety of febuxostat as well as from randomized ...
Katsiki, Niki, Borghi, Claudio
core +1 more source
, 2022 Hyperuricemic nephropathy (HN) is a common clinical complication of hyperuricemia. The pathogenesis of HN is directly related to urea metabolism in the gut microbiota.
Xiao Hui Tang (14280944) +8 more
core +1 more source